Latest Funding News

Anagenics Limited has revealed a significant 52.6% decline in revenue alongside an 83.5% increase in net loss for the financial year ended June 2025, marking a challenging period for the biotech company.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

EMVision Medical Devices reported a sharp increase in FY25 losses alongside a 51% revenue drop, yet marked significant progress in clinical trials for its innovative brain scanners and secured $8 million in government grants to fuel commercialisation.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.

Sequoia Financial Group reported a robust FY25 with a 13.7% rise in EBITDA and a 44% jump in funds under advice, underpinned by strategic restructuring and technology investments.

Lachlan Star Limited has raised $2.162 million through a share placement to fund critical drilling programs at its gold and copper projects in Western Australia and New South Wales.

Sequoia Financial Group reported a 13.7% rise in operating profit for FY25, driven by significant growth in funds under advice and operational efficiencies. The company declared a fully franked final dividend, signaling confidence despite ongoing regulatory investigations.

Sequoia Financial Group reported steady revenue but a sharp profit decline in FY25, driven by divestments and goodwill impairment. The company simplified its business structure and strengthened governance while maintaining dividend payouts.

Clinuvel Pharmaceuticals reports steady financial growth with an 8% rise in revenue and 2% profit increase, while expanding its US commercial footprint and completing recruitment for a pivotal vitiligo trial.

archTIS has successfully raised A$8.7 million through a fully underwritten placement and institutional entitlement offer, backing its strategic acquisition of Spirion LLC assets and expansion plans. A retail entitlement offer is set to follow, aiming to raise an additional A$11.7 million.

Beam Communications reports a pivotal FY25 marked by the divestment of its Zoleo joint venture, unlocking significant capital and delivering improved margins despite a statutory revenue decline. The company projects positive operating cash flow and growth in FY26.

Austral Gold Limited reported a net loss of US$1.3 million for the first half of 2025, while completing refurbishment of its Casposo plant to diversify production. Despite operational challenges and increased costs, the company leans on shareholder support and strategic investments to manage liquidity pressures.